United States Veterinary Pain Management Market - 2023-2030

United States Veterinary Pain Management Market - 2023-2030

Market Overview
The united states veterinary pain management market reached US$ XX million in 2022 and is projected to witness lucrative growth by reaching up to US$ XX million by 2030. The market is growing at a CAGR of 5.10% during the forecast period (2023-2030).

Veterinary pain management refers to the administration of various drugs and drug combinations to animals in order to provide relief from chronic pain. It entails watching for behavioral cues and predicting the type, severity, and duration of pain. Physical compression, massage, therapy, rehabilitation, acupuncture, laser therapy, and the administration of therapeutic and anti-anxiety medications are all part of the treatment. These medications can be taken orally, parenterally, or topically. Changes in housing conditions, diet, and level of interaction with other animals and humans are all part of veterinary pain management. It relieves acute surgical, traumatic, and disease-related pain while also improving the animal's overall health.

Market Dynamics
Increasing clinical trials for pain management in canines is likely to drive market growth.
According to the American Veterinary Medical Association, on January 3, 2023, North Carolina State University conducted a randomized controlled crossover study using the Chiari-like Malformation and Syringomyelia Evaluation (CHASE) Questionnaire to evaluate the safety and efficacy of pregabalin in dogs to evaluate how well a novel veterinary drug used to treat pain could treat the condition. The study will be completed by February 1st, 2024. Additionally, in 2022, Colorado State University conducted an intervention study on the effect of intravenous carboplatin on pain control in dogs with appendicular osteosarcoma. The drug's potential medical use is to reduce bone pain associated with tumors. The study will be completed by December 31, 2023. Thus, from the above factors, the market is expected to drive in the forecast period.
The high cost of veterinary pain management devices is expected to hamper market growth.

Laserconn Veterinary Pain Relief Therapy Treatment Device is used to treat pain, orthopedic diseases, wound healing and dental problems in pets (e.g. cats and dogs) and larger animals (e.g. ponies, horses, etc.). The device costs around $4,999. Hence, the market is expected to be hampered in the forecast period based on the above statements.

COVID-19 Impact Analysis
The COVID-19 pandemic is having an unprecedented impact on veterinarians, who play a critical role in protecting the health of animals and the public, ensuring the safety of our food supply, monitoring for zoonotic agents, and supporting biomedical research and medical countermeasures such as the development of COVID-19 diagnostics, treatments, and vaccines. Veterinary practices have been consistently cited as essential healthcare businesses throughout the pandemic. Veterinary professionals quickly adapted and responded to changing conditions and recommendations to protect customers, patients, animal health teams, veterinary students, and veterinary technician students while providing the veterinary services needed for all types of animals. Telemedicine and curbside care have been particularly important tools to monitor the health of animal patients and protect animal teams during the pandemic.

Additionally, several challenges have emerged for pain physicians during the COVID-19 pandemic, both in terms of the risk of harm from undertreatment and the risk of harm from improper treatment, as the interaction between painkillers and the immune system must be considered. Untreated chronic pain can compromise the immune system and induce immunosuppression in some animals. Therefore, the challenges during the pandemic have impacted the market and it is expected to improve gradually during the forecast period.

Segment Analysis
The united states veterinary pain management market is segmented based on product, route of administration, animal, application, and distribution Channel.

The rising pet adoption rate, growing mass income, and rising popularity of pet therapy for mental health issues contributed to growing the companion segment market share during the forecast period.
The companion segment is expected to generate notable profits in the stipulated time frame due to the rising pet adoption rate, growing mass income, increasing number of nuclear families, and increasing popularity of pet therapy for mental health issues. For example, according to the 2022 Pet Adoption Statistics, 4.1 million pets are adopted in America each year, 2 million dogs and 2.1 million cats respectively. In addition, 6.3 million animals come to animal shelters every year, including 3.1 million dogs and 3.2 million cats. As a result, spending on animal health is increasing. Based on the factors mentioned above, the market segment thus accounted for the largest market share in the forecast period.

Additionally, Immunization Programmes all over the globe is one of the key interventions for the protection of children from preventable life-threatening conditions. It is one of the largest immunization programmes in the world and a major public health intervention in the country. For instance, Immunization Programme in India was introduced in 1978 as the Expanded Programme of Immunization (EPI). The program gained momentum in 1985 and was expanded as Universal Immunization Programme (UIP) to be implemented in a phased manner to cover all districts in the country by 1989-90. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Competitive Landscape
The major players in the market include Assisi Animal Health, Ceva, Zoetis, Elanco, Iroko Pharmaceuticals, Boehringer Ingelheim and Vetoquinol S.A.

Why Purchase the Report?
• To visualize the united states veterinary pain management market segmentation based on the product, route of administration, animal, application, and distribution channel as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of united states veterinary pain management market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The united states veterinary pain management market report would provide approximately 38 tables, 35 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies


1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product
3.2. Snippet by Route of Administration
3.3. Snippet by Animal
3.4. Snippet by Application
3.5. Snippet by Distribution Channel
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing clinical trials for pain management in canines is likely to drive market growth.
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. The high cost of veterinary pain management devices is expected to hamper market growth.
4.1.2.2. XX
4.1.3. Opportunity
4.1.3.1. XX
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
7.1.2. Market Attractiveness Index, By Product
7.2. Drugs*
7.2.1. NSAIDs
7.2.2. Introduction
7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3.1. Meloxicam (Mobic, Vivlodex)
7.2.3.2. Etodolac (EtoGesic, Lodine)
7.2.3.3. Carprofen (Rimadyl)
7.2.3.4. Firocoxib (Equioxx, Previcox)
7.2.3.5. DERAMAXX
7.2.3.6. Metacam
7.2.3.7. Others
7.2.4. Opioid
7.2.4.1. Morphine (Roxanol)
7.2.4.2. Codeine (Codeine Contin, Codeine Phosphate, Codeine Sulfate, Codeine 15 or 30)
7.2.4.3. Duragesic (fentanyl transdermal)
7.2.4.4. Hydromorphone (Dilaudid)
7.2.4.5. Tramadol (Ultram, ConZip, Durela, Ralivia, Rybix, Ryzolt, Tridural, Zytram)
7.2.4.6. abapentin (Neurontin, Aclonium, Equipax, Gantin, Gabarone, Gralise)
7.2.4.7. Amantadine (Symmetrel, Gocovri, Osmolex ER, Endantadine)
7.2.4.8. Others
7.3. Devices
7.3.1.1. Laser Therapy
7.3.1.2. Electromagnetic Therapy
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Parenteral
8.4. Topical
9. By Animal
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal
9.1.2. Market Attractiveness Index, By Animal
9.2. Companion Animal*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Livestock
10. By Application
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.1.2. Market Attractiveness Index, By Application
10.2. Osteoarthritis and Joint Pain*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Postoperative Pain
10.4. Cancer
10.5. Others
11. By Distribution Channel
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Veterinary Hospital Pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies
11.5. Others
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Assisi Animal Health*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Ceva
13.3. Zoetis
13.4. Elanco
13.5. Iroko Pharmaceuticals
13.6. Boehringer Ingelheim
13.7. Vetoquinol S.A.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings